Single-cell analysis of CML patients bone marrow at diagnosis reveals coexistence of CD26-CD35+ healthy stem cells and CD26+CD35- CML stem cells, and how the ratio between these impacts TKI response.

The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved ...